© 2017 Evestra, Inc.


Evestra has established a network of US and international organizations with experience in hot melt extrusion, from academic laboratories to commercial manufacturing. Technology development is based on the extensive experience of our teams of staff members and scientific advisors. The established and expanding IP portfolio enables the targeted delivery of drugs in a variety of women's healthcare areas such as fertility control, hormone replacement therapy and gynecological indications.

Evestra has established the capability to develop its products through clinical proof-of-concept (POC) to commercialization. Partnerships play an important role in the overall development strategy, either to finance development through grants from philanthropic partners or license agreements with commercial partners. The most important partnerships are as follows:

Gedeon Richter. In 2013, Evestra established its first corporate partnership with the Hungarian company, Gedeon Richter. Under this agreement, Evestra received R&D support, milestone payments, and double-digit royalties in exchange for marketing rights in Europe and Latin America. Evestra has retained marketing rights for the US and other rest-of-the-world territories.  Since then, two additional partnership deals have been signed.  The first of these is for a second-generation vaginal ring contraceptive and the same one is a vaginal ring for overactive bladder.

Glenmark. In 2016, Evestra established its first corporate partnership in the US with Glenmark, a company based in India with a strong presence in the US as a generic and innovative drug company. Glenmark’s interests are focused on “high-hurdle” generic women’s health products such as vaginal rings. Under the agreement with Glenmark, Evestra receives R&D support, milestone payments and double-digit royalties in exchange for marketing rights in the US. 

Gates Foundation. The Gates Foundation is one of the largest philanthropic organizations focusing on new treatments for under-served indications and patient populations. Evestra was selected by Gates to work on one of their goals – that of serving women in developing countries by developing a safe and effective contraceptive injectable contraceptive that works for at least six months. Gates has funded all R&D efforts so far in exchange for the commercialization rights in developing countries. Evestra remains in possession of commercialization rights in the developed world and actually sees significant sales potential for certain patient populations in Latin America, US and Europe.

For certain key technology and drug development activities, strategic collaborations have been established with qualified partners, including:

· Research Center of Pharmaceutical Engineering in Graz, Austria, for vaginal ring product development;

· SocraTec R&D GmbH and Dinox GmbH in Germany, for clinical development;

· Institute for “Versuchstierkunde” in Jena, Germany, for conducting research with animal models

Through CROs, the Company also has established drug development capabilities